ctDNA-guided chemo after liver surgery for colon cancer
Part of Cancer, Digestive system clinical trials.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old and able to consent; any gender is allowed.
- You have had chemotherapy before surgery (neoadjuvant chemotherapy).
- Your liver and tumor were removed with an R0 surgery result (fully removed); some limited liver treatments like ablation count if they achieved similar results.
- Your ctDNA blood test after surgery is negative (no cancer signal detected).
- Your health is good enough for chemotherapy (ECOG 0–2 and/or ASA below IV).
- You do not have cancer spread to other distant areas besides the liver, and you don’t have pregnancy or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
This trial uses a blood test (ctDNA, a sign of cancer cells shedding into the blood) to help guide chemotherapy after surgery to remove colorectal liver metastases. It may help patients get the right chemotherapy plan after their operation, potentially based on whether cancer material is still detectable.
This study tests whether a special blood test (looking for cancer DNA) can help doctors decide if you need chemotherapy after colorectal cancer surgery. The goal is to avoid unnecessary chemotherapy while making sure patients who need it get treated.
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.